Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for

See also
Status	Clinical Trial	Phase
Completed	`NCT00685854` - Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth	Phase 1
Recruiting	`NCT01975103` - Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases	Phase 2
Recruiting	`NCT03845049` - Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1	Phase 3
Completed	`NCT03321916` - MacTel Laser Study	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT00685854 - Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Phase 1

Recruiting

NCT01975103 - Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases

Phase 2

Recruiting

NCT03845049 - Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Phase 3

Completed

NCT03321916 - MacTel Laser Study

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03071965
Study type	Interventional
Source	Neurotech Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	May 12, 2017
Completion date	May 11, 2021

Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms